US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Executive Summary
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.